04.01.2018 • News

Celanese Acquiring Custom Compounder

(c) Celanese
(c) Celanese

US chemicals and plastics producer Celanese is acquiring custom compounder Omni Plastics for an undisclosed sum. The subsidiaries of the Evansville, Indiana-based compounder, including distributor Resinal de Mexico in Mexico City, Mexico, are part of the deal expected to close during the first quarter, following all approvals.

Dallas, Texas-headquartered Celanese said the acquisition "further strengthens" its global asset base by adding compounding capacity in the Americas. It plans to integrate the products and production facilities into its engineered materials business, which formerly traded as Ticona.

The portfolio additions will include a variety of formulations in PA, PP, PC, PBT and ABS for applications in automotive, appliances, office furniture and lawn & garden, along with compounds for pump housings, wheels, handles, mounting brackets, levers and pressure vessels. Other new assets include formulations used in electronic applications and functional compounds with properties such as flame retardant or improved optical clarity.

Several of Omni’s product grades are UL-listed, FDA-compliant, NSF-compliant and made with post-industrial material, Celanese said. They are also qualified with automotive, E&E and other original equipment manufacturers.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read